{"title":"Effect of Tirofiban Combined with Neurointerventional Therapy on Neurological Function of Patients with Acute Cerebral Infarction","authors":"Yongfei Jiang, Lesheng Wang, Wenze Li","doi":"10.26689/cnr.v1i2.5378","DOIUrl":null,"url":null,"abstract":"Objective: To analyze the effect of tirofiban combined with neurointerventional therapy on neurological function of patients with acute cerebral infarction. Methods: 70 patients with acute cerebral infarction admitted between January 2022 and January 2023 were selected as research objects, and patients were divided into control group (neurological interventional therapy) and experimental group (tirofiban combined with neurointerventional therapy) according to the computerized grouping method. The treatment outcomes of both groups were compared. Results: The efficacy of the treatment in the experimental group was 94.9%, which was significantly higher that of the control group control group at 77.14% (P < 0.05). Before treatment, there was no difference in the National Institutes of Health Stroke Scale and Barthel Index between the control group and the experimental group (P < 0.05); after treatment, the NIHSS score of the experimental group was lower than that of the control group, and the BI score was higher than that of the control group (P < 0.05). Before treatment, there was no difference in the levels of high-sensitivity C-reactive protein (hs-CRP) and neuron-specific enolase (NSE) between the control group and the experimental group (P < 0.05); after treatment, the levels of hs-CRP and NSE in the experimental group were lower than those in the control group (P < 0.05). Before treatment, there was no difference in the levels of carbon monoxide (CO), endothelin (ET), nerve growth factor (NGF), and myelin basic protein (MBP) between the control group and the experimental group (P < 0.05); after treatment, the levels of CO and NGF in the experimental group were higher than those in the control group, and the levels of ET and MBP were lower than those in the control group, with statistical significance (P < 0.05). Conclusion: Tirofiban combined with neurointervention is effective in treating acute cerebral infarction. It can not only control the development of the disease, but also improve the patients’ neurological function and the quality of life.","PeriodicalId":87465,"journal":{"name":"Clinical neuroscience research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical neuroscience research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26689/cnr.v1i2.5378","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To analyze the effect of tirofiban combined with neurointerventional therapy on neurological function of patients with acute cerebral infarction. Methods: 70 patients with acute cerebral infarction admitted between January 2022 and January 2023 were selected as research objects, and patients were divided into control group (neurological interventional therapy) and experimental group (tirofiban combined with neurointerventional therapy) according to the computerized grouping method. The treatment outcomes of both groups were compared. Results: The efficacy of the treatment in the experimental group was 94.9%, which was significantly higher that of the control group control group at 77.14% (P < 0.05). Before treatment, there was no difference in the National Institutes of Health Stroke Scale and Barthel Index between the control group and the experimental group (P < 0.05); after treatment, the NIHSS score of the experimental group was lower than that of the control group, and the BI score was higher than that of the control group (P < 0.05). Before treatment, there was no difference in the levels of high-sensitivity C-reactive protein (hs-CRP) and neuron-specific enolase (NSE) between the control group and the experimental group (P < 0.05); after treatment, the levels of hs-CRP and NSE in the experimental group were lower than those in the control group (P < 0.05). Before treatment, there was no difference in the levels of carbon monoxide (CO), endothelin (ET), nerve growth factor (NGF), and myelin basic protein (MBP) between the control group and the experimental group (P < 0.05); after treatment, the levels of CO and NGF in the experimental group were higher than those in the control group, and the levels of ET and MBP were lower than those in the control group, with statistical significance (P < 0.05). Conclusion: Tirofiban combined with neurointervention is effective in treating acute cerebral infarction. It can not only control the development of the disease, but also improve the patients’ neurological function and the quality of life.